Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
Breath test could predict response to immunotherapy
The test detects certain levels of chemicals and an online tool then uses the data to determine if the patient would respond to certain immunotherapies, including checkpoint inhibitor drugs. ... These therapies have been an important step forward in the
Latest news
-
Bluebird Bio reveals further encouraging data for CALD gene therapy
Lenti-D is Bluebird’s lead gene therapy programme, but the company has also made significant progress with its Celgene-partnered CAR-T cancer immunotherapy programme, reporting dramatic responses with its
-
Aimmune gets FDA panel backing for peanut allergy therapy
Eight of the specialists also agreed that the oral immunotherapy was safe, which is a relief to the company as FDA briefing documents published ahead of the meeting highlighted that patients ... of rivals including DBV Technologies which has a
-
Roche scores EU approval twice for Tecentriq in lung cancer
immunotherapy Tecentriq, in both extensive-stage small cell lung cancer (ES-CLC) and non-squamous non-small cell lung cancer (NSCLC). ... The approval in ES-CLC is the first cancer immunotherapy approved in Europe in this indication as an initial
-
Third strike for BMS’ Opdivo in brain cancer
new cancer immunotherapies might improve their prospects.
-
ALK-Abello debuts its birch pollen allergy therapy in Germany
Key market for the new product. Danish drugmaker ALK-Abello has launched its tree pollen immunotherapy Itulazax in Germany, its first market, following its European approval earlier this year. ... The sublingual allergy immunotherapy or ‘SLIT’ drug
More from news
Approximately 86 fully matching, plus 448 partially matching documents found.
Latest Intelligence
-
Encouraging signs in biomarker R&D
ASCO expert, Catherine S Magid Diefenbach said assay developers and the immunotherapy industry have ramped-up their biomarker R&D efforts. ... The potential downside, Magid Diefenbach said, is that immunotherapy firms may focus drug development on
-
Brain power: fresh approaches to Alzheimer’s drug discovery
The development of immunotherapies has, in recent years, dominated our progress in tackling cancer and Alector’s approach in harnessing the power of the immune system to target neurodegeneration was a
-
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019? ... cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies.
-
Immunotherapy combination trials Q&A
By Chris Learn and Martin Lachs
-
AstraZeneca’s oncology renaissance
olaparib) plus biologic PD-L1 immunotherapy Imfinzi (durvalumab).
More from intelligence
Approximately 5 fully matching, plus 48 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.
-
BMS appoints new commercial leader, Davies joins Eisai and more
The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy. ... Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as
-
Industry appointments
Zelluna Immunotherapy appoints CSO. Norwegian biotech Zelluna Immunotherapy has named Namir Hassan as its chief scientific officer (CSO). ... antigen. Hassan’s new role, however, will see him manage and plan the next stages of development for the TCR
-
Zelluna Immunotherapy appoints chief technology officer
Arjan Roozen will consolidate the biotech’s manufacturing strategy. Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.
-
Targovax strengthens board of directors
of our novel and complementary portfolio of cancer immunotherapies.”.
More from appointments
Approximately 2 fully matching, plus 43 partially matching documents found.
Latest from PMHub
-
Precision paediatrics: Treating patients with CAR-T
SA: CAR-T cell therapy is an innovative immunotherapy that modifies the body’s own immune T-cells to start attacking cancer cells. ... Immunotherapy has been around for many years, but this is the first time that the patients’ own T-cells have been
-
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. ... OncoSec's lead immunotherapy platform – TAVO (tavokinogene
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
There is a strong unmet medical need for novel immunotherapy approaches such as TAVO. ... Presented at: Society for Immunotherapy of Cancer 33rd Annual Meeting; November 7–11, 2018; Washington, DC.
-
Lucid Group welcomes new magical talent and boosts their medical writing teams with hires in the US and UK
With three years’ healthcare communications experience, and a wealth of knowledge in epilepsy, immunotherapy and oncology Andrew comments, “I have had a very fulfilling first two months at Lucid; the team
-
SWITCHED ONcology Patient Experience Focus Group Full Discussion
The focus group provided deeper insight in to a number of themes including the transformation of cancer understanding, the barriers to cancer diagnosis, the advent of new treatments including immunotherapy, communication
More from PMHub
Approximately 11 fully matching, plus 15 partially matching documents found.
Featured jobs
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Senior Medical Writer
-
Competitive salary plus benefits
- Account Manager – Healthcare advertising
-
Salary TBC
-
Events Executive
-
DOE
-
Account Director – UK Office
-
Excellent salary and benefits
- Client Services Director- Flexible Working
-
Negotiable
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- Envision Pharma Group relocates to support expansion
- Biogen loses another pipeline drug to toxicity concerns
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Half of European cancer drug trials ‘biased’, says BMJ
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Report: Customer experience, shaping digital healthcare
- In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
- Encouraging signs in biomarker R&D
- The cancer immunotherapy firms ramping-up biomarker R&D...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Quick links
Infographics
